Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study

Nettis, Eustachio; Ferrucci, Silvia; Ortoncelli, Michela; Pellacani, Giovanni; Foti, Caterina; Leo, Elisabetta; Patruno, Cataldo; Rongioletti, Franco; Argenziano, Giuseppe; Macchia, Luigi; Tavecchio, Simona; Napolitano, Maddalena; Ribero, Simone; Bonzano, Laura; Romita, Paolo; Bona, Danilo Di; Nisticò, Steven Paul; Piras, Viviana; Calabrese, Giulia; Detoraki, C; Carbonara, Monica; Fabbrocini, Gabriella

doi:10.18176/jiaci.0641

Cited by 40 publications

(43 citation statements)

References 41 publications

(108 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 8 The EASI-50 (85.7%–98.1%) and EASI-75 (60.6%–81.5%) response rates at week 16 with concomitant medications in the real clinical practice were reported to be higher in recently published real-world studies than in our study. 11 24 25 26 In these real-world studies, dupilumab was administered biweekly, which may explain why the clinical outcomes were better in those studies than in our study.…”

Section: Discussionmentioning

confidence: 67%

Real Clinical Practice Data of Monthly Dupilumab Therapy in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Clinical Efficacy and Predictive Markers for a Favorable Clinical Response

Lee

Kim

Nahm

2021

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

Purpose Dupilumab is recommended to be administered biweekly to treat adult patients with moderate-to-severe atopic dermatitis (AD). Real clinical practice data on the clinical efficacy of monthly dupilumab therapy are limited. We analyzed real clinical practice data on the clinical efficacy of monthly dupilumab therapy and predictive markers for favorable clinical responses to the therapy. Methods Medical records of 57 adult patients with moderate-to-severe AD who received dupilumab therapy every 4 weeks for 16 weeks were analyzed retrospectively. Eczema Area and Severity Index (EASI) were recorded at baseline and week 16. Clinical responses to monthly dupilumab therapy were defined as the proportion of patients with decreased EASI scores of at least 50% or 75% from baseline at week 16 (EASI-50 or EASI-75). Blood eosinophil counts and serum lactate dehydrogenase (LDH) levels were measured at baseline and week 16. Results Monthly dupilumab therapy showed EASI-50 and EASI-75 clinical responses in 48 (84.2%) and 27 (47.4%) of 57 patients at week 16, respectively. The percentage decrease in EASI scores from baseline at week 16 was significantly inversely correlated with baseline blood eosinophil count (correlation coefficient [ r ] = −0.405, P = 0.002) and baseline serum LDH level ( r = −0.466, P < 0.001). The EASI-75 response rate was higher in patients with low (< 500/µL, 73.3%) than in those with high (≥ 500/µL, 37.5%) baseline blood eosinophil counts ( P = 0.032), and was higher in patients with low (< 400 U/L, 55.6%) than those with high (≥ 400 U/L, 10.0%) baseline serum LDH levels ( P = 0.013). Conclusions Monthly dupilumab therapy was clinically effective in adult patients with moderate-to-severe AD in real clinical practice. Baseline blood eosinophil count and serum LDH level could be predictive markers for clinical response to dupilumab therapy.

show abstract

Section: Discussionmentioning

confidence: 67%

Real Clinical Practice Data of Monthly Dupilumab Therapy in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Clinical Efficacy and Predictive Markers for a Favorable Clinical Response

Lee

Kim

Nahm

2021

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

show abstract

“…Real-world evidence of the effectiveness and safety of dupilumab for atopic dermatitis Accumulating real-world evidence has ensured the effectiveness and tolerable safety of dupilumab both in the short term and in the long term. The articles searched in PubMed and Google Scholar are shown in Table 1 (Ariëns et al, 2020, Ariëns et al, 2021, Faiz et al, 2019, Fargnoli et al, 2020, Fargnoli et al, 2019, Jang et al, 2020, Jo et al, 2020a, Kreeshan et al, 2021, Matsutani et al, 2020, Nettis et al, 2020b, Nettis et al, 2020c, Olesen et al, 2019, Patruno et al, 2021a, Patruno et al, 2021b, Quint et al, 2020, Ribero et al, 2020, Sears et al, 2020, Tauber et al, 2019, Uchida et al, 2021, Uchida et al, 2019. Patruno et al reported the effectiveness and safety of dupilumab in elderly patients with AD in real life (Patruno et al, 2021a, Patruno et al, 2021b.…”

Section: Effectiveness and Safety Of Dupilumab For Atopic Dermatitis In The Real Worldmentioning

confidence: 99%

“…Accumulating real-world evidence has ensured the effectiveness and tolerable safety of dupilumab both in the short term and in the long term. The articles searched in PubMed and Google Scholar are shown in Table 1 ( Ariëns et al., 2021 , 2020 ; Armario-Hita et al., 2019 ; Faiz et al., 2019 ; Fargnoli et al, 2020 , 2019 ; Ferrucci et al., 2020 ; Jang et al., 2020 ; Jo et al., 2020a , 2020b ; Kim et al., 2020 ; Kreeshan et al., 2021 ; Matsutani et al., 2020 ; Nettis et al., 2020b , 2020c ; Olesen et al., 2019 ; Patruno et al., 2021a , 2021b ; Quint et al., 2020 ; Ribero et al., 2020 ; Sears et al., 2021 ; Tauber et al., 2019 ; Tavecchio et al., 2020 ; Uchida et al., 2021 , 2019 ; Wang et al., 2020 ; Yamauchi et al., 2021 ). Patruno et al.…”

Section: Effectiveness and Safety Of Dupilumab For Ad In The Real Worldmentioning

confidence: 99%

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Kamata

Tada

2021

JID Innovations

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…The combination of Dennie-Morgan fold and POH is highly suspicious for atopic dermatitis [2]. Atopic dermatitis is probably the most common dermatosis associated with POH [3]. Several medical drugs may cause POH, such as prostaglandins or imatinib [4,5].…”

Section: Introductionmentioning

confidence: 99%

Periorbital Hyperpigmentation—Dark Circles under the Eyes; Treatment Suggestions and Combining Procedures

2021

View full text Add to dashboard Cite

Periorbital hyperpigmentation (POH) is a frequent concern among both young and adult patients. The etiology is multifactorial with a genetic background. Prevalence is higher in darker skin types. It has been estimated as high as 30% in a recent Indian study. Females are often more disappointed by POH than males. Treatment has to consider underlying pathologies and patients’ needs. We present our treatment algorithm for POH. In this study, 74 patients with POH, 64 females (86.5%) and 10 males (13.3%), were treated. Of these, 39 patients (53%) had a family history of POH. The age range of patients was 18−57 years (average: 36.1 years). In case of tear trough deformity, soft tissue augmentation was used by injection of hyaluronic acid gel, calcium hydroxylapatite, or autologous fat. Blepharoplasty with partial fat pad resection or repositioning via arcus marginalis release was used to correct severe orbital fat herniation and excess of the lower lid skin. Melanin hyperpigmentation of the skin was improved by sessions of Q-switched 1064 and 532 nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser. Small vessels (capillaries and veins) were targeted by a 1064 nm long-pulsed Nd-YAG laser. Sessions of intense pulsed light (IPL) or CO2 fractional laser were employed to improve skin texture and fine lines. Topical hyaluronic acid-based formulations may be used as adjuvant self-treatment by patients. For pigmented and mixed-type POH, ultraviolet light protection is recommended as a maintenance treatment. By the use of various technologies, treatment can be individually tailored.

show abstract

Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study

Cited by 40 publications

References 41 publications

Real Clinical Practice Data of Monthly Dupilumab Therapy in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Clinical Efficacy and Predictive Markers for a Favorable Clinical Response

Real Clinical Practice Data of Monthly Dupilumab Therapy in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Clinical Efficacy and Predictive Markers for a Favorable Clinical Response

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Periorbital Hyperpigmentation—Dark Circles under the Eyes; Treatment Suggestions and Combining Procedures

Contact Info

Product

Resources

About